Man Group plc increased its stake in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) by 18.2% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 145,709 shares of the biotechnology company’s stock after purchasing an additional 22,433 shares during the quarter. Man Group plc owned approximately 0.15% of Momenta Pharmaceuticals worth $1,888,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. lifted its holdings in Momenta Pharmaceuticals by 2.6% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 572,669 shares of the biotechnology company’s stock worth $7,130,000 after purchasing an additional 14,274 shares during the last quarter. State of Tennessee Treasury Department lifted its holdings in Momenta Pharmaceuticals by 9.4% in the 3rd quarter. State of Tennessee Treasury Department now owns 71,810 shares of the biotechnology company’s stock worth $931,000 after purchasing an additional 6,169 shares during the last quarter. DekaBank Deutsche Girozentrale lifted its holdings in Momenta Pharmaceuticals by 43.8% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 64,000 shares of the biotechnology company’s stock worth $791,000 after purchasing an additional 19,490 shares during the last quarter. Point72 Asset Management L.P. lifted its holdings in Momenta Pharmaceuticals by 1,147.0% in the 3rd quarter. Point72 Asset Management L.P. now owns 2,581,229 shares of the biotechnology company’s stock worth $33,453,000 after purchasing an additional 2,374,229 shares during the last quarter. Finally, Russell Investments Group Ltd. acquired a new stake in Momenta Pharmaceuticals in the 3rd quarter worth approximately $1,182,000. Hedge funds and other institutional investors own 97.04% of the company’s stock.

A number of research analysts have recently commented on MNTA shares. Piper Jaffray Companies set a $35.00 price target on Momenta Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, September 17th. SunTrust Banks started coverage on Momenta Pharmaceuticals in a report on Tuesday, November 12th. They set a “buy” rating and a $29.00 price target for the company. BidaskClub upgraded Momenta Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday. HC Wainwright started coverage on Momenta Pharmaceuticals in a report on Wednesday, September 25th. They set a “buy” rating and a $24.00 price target for the company. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $29.00 price target on shares of Momenta Pharmaceuticals in a report on Thursday, October 24th. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $23.45.

Shares of MNTA stock opened at $16.72 on Friday. Momenta Pharmaceuticals, Inc. has a 12 month low of $9.51 and a 12 month high of $18.39. The firm has a market cap of $1.66 billion, a PE ratio of -8.24 and a beta of 2.07. The stock has a 50 day moving average of $16.16 and a 200-day moving average of $13.27.

Momenta Pharmaceuticals (NASDAQ:MNTA) last issued its quarterly earnings results on Thursday, October 31st. The biotechnology company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.09). Momenta Pharmaceuticals had a negative return on equity of 59.82% and a negative net margin of 361.66%. The business had revenue of $6.40 million for the quarter, compared to analyst estimates of $5.24 million. During the same quarter last year, the firm earned ($0.65) earnings per share. The firm’s quarterly revenue was down 57.0% compared to the same quarter last year. On average, equities analysts expect that Momenta Pharmaceuticals, Inc. will post -2.58 EPS for the current fiscal year.

In other news, insider Anthony M. Manning sold 6,365 shares of the business’s stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $13.83, for a total transaction of $88,027.95. Following the sale, the insider now directly owns 20,603 shares in the company, valued at $284,939.49. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Craig A. Wheeler sold 33,334 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $16.69, for a total value of $556,344.46. Following the sale, the chief executive officer now owns 46,011 shares in the company, valued at $767,923.59. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 177,262 shares of company stock valued at $2,862,158. Corporate insiders own 3.40% of the company’s stock.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy.

Further Reading: Management Fee

Institutional Ownership by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.